Cancer clinical trials in the region Nouvelle-Aquitaine

410 currently recruiting clinical trials
Region Nouvelle-Aquitaine

Phase 3 Prostate cancer #NCT07028853 #2024-519369-24-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Hormone-sensitive
Required number of previous lines of therapy for current stage of disease
None
Excluded previous treatments at advanced or metastatic stage
Chemotherapy
12 recruiting sites
Pfizer
Phase 3 Lung cancer #NCT07361510 #2025-523586-18-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Bristol-Myers Squibb
Phase 3 Skin cancer #NCT05078047
Required histologic types
Melanoma Basal cell carcinoma Squamous cell carcinoma Merkel cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
24 recruiting sites
UNICANCER
Phase 3 Skin cancer #NCT05549297
Required histologic types
Melanoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Immunocore Ltée
Phase 3 Colon cancer Rectal cancer Anal cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Small intestine and appendix cancer #NCT07087054 #2024-519875-24-00
Required histologic types
Ileum cancer
Required histologic sub types
Neuroendocrine tumor
Required number of previous lines of therapy for current stage of disease
None
6 recruiting sites
Crinetics Pharmaceuticals Inc.
Phase 3 Colon cancer Rectal cancer #NCT07228832 #2025-521587-35-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
BRAF MSI/dMMR
Excluded previous treatments at localized stage
Immunotherapy Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Targeted therapy
8 recruiting sites
Summit Therapeutics
Phase 3 Acute leukemia #NCT07211958 #2025-522279-27-00
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None Treated / Controled
Required genetic anomalies
NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
2 recruiting sites
Syndax Pharmaceuticals
Phase 3 Lymphoma CLL & Richter's syndrome #NCT06104566 #2023-508005-24-00
Required histologic types
B cell lymphoma CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required number of previous lines of therapy
1
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
12 recruiting sites
Ascentage Pharma Group Inc.
Phase 3 Colon cancer Rectal cancer #NCT06642844
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Centre Hospitalier Universitaire de Tours
Phase 3 Breast cancer #NCT05696626 #2023-503708-10-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ESR
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded genetic anomalies
Other mutation
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Sermonix Pharmaceuticals Inc.